



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 1 209 233 A2

EUROPEAN PATENT APPLICATION

(12)

(43) Date of publication:
29.05.2002 Bulletin 2002/22

(51) Int Cl.7: C12N 15/57, C12N 9/54,
C12N 1/21, C11D 3/386

(21) Application number: 01127851.2

(22) Date of filing: 22.11.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.11.2000 JP 2000355166
12.04.2001 JP 2001114048

(71) Applicant: Kao Corporation
Tokyo 103-8210 (JP)

(72) Inventors:
• Hatada, Yuji
Mihara-shi, Hiroshima 723-0052 (JP)
• Ogawa, Akinori
Haga-gun, Tochigi 321-3497 (JP)

- Kageyama, Yasushi
Haga-gun, Tochigi 321-3497 (JP)
- Sato, Tsuyoshi
Haga-gun, Tochigi 321-3497 (JP)
- Araki, Hiroyuki
Haga-gun, Tochigi 321-3497 (JP)
- Sumitomo, Nobuyuki
Haga-gun, Tochigi 321-3497 (JP)
- Okuda, Mitsuyoshi
Haga-gun, Tochigi 321-3497 (JP)
- Saeki, Katsuhisa
Haga-gun, Tochigi 321-3497 (JP)

(74) Representative: VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)

(54) Alkaline proteases

(57) Provided are an alkaline protease wherein an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from: at position (a): an arginine residue, at position (b): a proline residue, at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue, and at position (d): an aspartic acid residue; an alkaline protease wherein an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 has been deleted or selected from: at position (e): a glutamine, aspartic acid or like residue, at position (f): a lysine, serine or like residue, at position (g): a tyrosine

or tryptophan residue, at position (h): a tryptophan, phenylalanine or like residue, at position (i): a tryptophan, phenylalanine or like residue, at position (j): an alanine or lysine residue, at position (k): a lysine, arginine or like residue, and at position (l): a valine or isoleucine residue; a gene encoding the alkaline protease; a recombinant vector containing the gene, a transformant containing the recombinant vector; and a detergent composition containing the alkaline protease.

The present invention makes it possible to provide alkaline proteases having activity even in the presence of a high concentration of fatty acids, having high specific activity and detergency and being useful as an enzyme to be incorporated in a detergent.

EP 1 209 233 A2

Description

[0001] The present invention relates to alkaline proteases having high specific activity and strong oxidant resistance and as an enzyme to be added to a detergent, having excellent detergency.

[0002] Proteases have conventionally been used in a variety of fields such as various detergents including laundry detergents, cosmetics, bath agents, food modifiers, and pharmaceuticals such as digestion aids and anti-inflammatory agents. Among them, proteases for detergents are industrially produced in the largest amount and have a great market scale. A number of proteases are now put on the market.

[0003] In most cases, stains on clothes contain not only proteins but also plural components such as lipids and solid particles. There is accordingly a demand for detergents having detergency high enough to remove such actual complex stains. Finding, from such a viewpoint, alkaline proteases capable of retaining caseinolytic activity even in the presence of a high concentration of fatty acids and exhibiting excellent detergency even if the stain is composed of not a simple protein component but plural components, for example, protein and lipid, and having a molecular weight of about 43,000, the present inventors applied a patent (WO99/18218) on them.

[0004] Alkaline proteases superior to the above-described ones in specific activity, oxidant resistance and detergency and usable for detergents of wide-ranging compositions have however been requested.

[0005] The present inventors searched for such alkaline proteases mainly from enzyme variants. The above-described alkaline proteases are however utterly different in enzymological properties from serine proteases typified by subtilisin so that the modified site of subtilisin did not provide them with useful information. As a result of a further investigation, the present inventors have found that in order to obtain novel alkaline proteases having improved specific activity, stability against an oxidant and detergency while maintaining the properties of the above-described alkaline proteases, they must have a specific amino acid residue at a predetermined position of their amino acid sequence.

[0006] In one aspect of the present invention, there is thus provided an alkaline protease wherein an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from:

at position (a): an arginine residue,

at position (b): a proline residue,

at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue, and

at position (d): an aspartic acid residue.

[0007] In another aspect of the present invention, there is also provided an alkaline protease wherein an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 of SEQ ID NO:1, or at a position corresponding thereto has been deleted or selected from:

at position (e): a glutamine, aspartic acid, serine, glutamic acid, alanine, threonine, leucine, methionine, cysteine, valine, glycine or isoleucine residue

at position (f): a lysine, serine, glutamine, phenylalanine, valine, arginine, tyrosine, leucine, isoleucine, threonine, methionine, cysteine, tryptophan, aspartic acid, glutamic acid, histidine, proline or alanine residue,

at position (g): a tyrosine, tryptophan, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, lysine, glutamine, methionine or cysteine residue,

at position (h): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, histidine, serine, lysine, glutamine, methionine, glycine, aspartic acid, proline, arginine or cysteine residue,

at position (i): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, glutamine, methionine or cysteine residue,

at position (j): an alanine or lysine residue,

at position (k): a lysine, arginine, alanine or serine residue, and

at position (l): a valine or isoleucine residue.

[0008] In a further aspect of the present invention, there are also provided a gene encoding the alkaline protease, a recombinant vector containing the gene and a transformant containing the vector.

[0009] In a still further aspect of the present invention, there is also provided a detergent composition containing the alkaline protease.

FIG. 1 is a diagram illustrating detergency of an alkaline protease variant;

FIG. 2 is a diagram illustrating relative specific activity of each of alkaline protease variants; and FIG. 3 is a diagram illustrating relative residual activity of each of alkaline protease variants after treatment with an oxidant.

[0010] As described above, in the alkaline proteases of the present invention, an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from: at position (a): an arginine residue, at position (b): a proline residue, at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue, and at position (d): an aspartic acid residue; or an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from: at position (e): a glutamine, aspartic acid, serine, glutamic acid, alanine, threonine, leucine, methionine, cysteine, valine, glycine or isoleucine residue, at position (f): a lysine, serine, glutamine, phenylalanine, valine, arginine, tyrosine, leucine, isoleucine, threonine, methionine, cysteine, tryptophan, aspartic acid, glutamic acid, histidine, proline or alanine residue, at position (g): a tyrosine, tryptophan, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, lysine, glutamine, methionine or cysteine residue, at position (h): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, histidine, serine, lysine, glutamine, methionine, glycine, aspartic acid, proline, arginine or cysteine residue, at position (i): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, glutamine, methionine or cysteine residue, at position (j): an alanine or lysine residue, at position (k): a lysine, arginine, alanine or serine residue, and at position (l): a valine or isoleucine residue.

[0011] Specifically, the alkaline proteases according to the present invention mean alkaline proteases having an amino acid sequence represented by SEQ ID NO:1 wherein the amino acid residue at a position selected from the above-described (a) to (d) and (e) to (l) has been deleted or predetermined, or another alkaline protease wherein the amino acid residue at a position corresponding thereto has been deleted or predetermined. They may be wild type enzymes, wild type variants or artificial variants.

[0012] The "another alkaline protease" may be a wild type enzyme or a wild type variant. That having oxidant resistance and having a molecular weight, as determined by SDS-PAGE, of $43,000 \pm 2,000$ is preferred, of which that having an amino acid sequence showing at least 60% homology with the amino acid sequence of SEQ ID NO:1 is more preferred. Particularly preferred is that having an amino acid sequence showing at least 60% homology with the amino acid sequence of SEQ ID NO:1, having oxidant resistance, works on the alkaline side (pH 8 or greater), is stable with at least 80% residual activity when treated at pH 10 for 10 minutes even at 50°C, is inhibited by diisopropyl fluorophosphate (DFP) and phenylmethane sulfonyl fluoride (PMSF) and has a molecular weight, as determined by SDS-PAGE, of $43,000 \pm 2,000$. The term "having oxidant resistance" as used herein means that it has at least 50% of residual activity (synthetic substrate assay) when treated in a 50 mM hydrogen peroxide solution (containing 5 mM calcium chloride) at pH 10 (a 20 mM Britton-Robinson buffer) at 20°C for 20 minutes.

[0013] Examples of the "alkaline protease having an amino acid sequence represented by SEQ ID NO:1" include KP43 [derived from *Bacillus* sp. strain KSM-KP43 (FERM BP-6532), WO99/18218], while those of the "alkaline protease having an amino acid sequence showing at least 60% homology with the amino acid sequence of SEQ ID NO:1" include protease KP9860 having an amino acid sequence represented by SEQ ID NO:2 [derived from *Bacillus* sp. strain KSM-KP9860 (FERM BP-6534), WO99/18218], Protease E-1 having an amino acid sequence represented by SEQ ID NO:3 [derived from *Bacillus* sp. strain No. D-6 (FERM P-1592), JP740710], Protease Ya having an amino acid sequence represented by SEQ ID NO:4 [derived from *Bacillus* sp. strain Y (FERM BP-1029), JP861210], Protease SD521 having an amino acid sequence represented by SEQ ID NO:5 [derived from *Bacillus* sp. strain SD-521 (FERM BP-11162), JP910821], Protease A-1 having an amino acid sequence represented by SEQ ID NO:6 (derived from NCIB12289, WO8801293), and Protease A-2 having an amino acid sequence represented by SEQ ID NO:7 (derived from NCIB12513, WO8801293). Of these, the amino acid sequences selected from SEQ ID NOS. 2 to 7 or alkaline proteases showing at least 80%, more preferably at least 90%, especially at least 95% homology therewith are preferred.

[0014] The homology of an amino acid sequence is calculated by Lipman-Pearson's method (Science, 227, 1435 (1985)).

[0015] The "amino acid residue at a corresponding position" can be identified by comparing amino acid sequences by using known algorithm, for example, that of Lipman-Pearson. The position of the "amino acid residue at a corresponding position" in the sequence of each protease can be determined by aligning the amino acid sequence of the protease in such a manner. It is presumed that the corresponding position exists at the three-dimensionally same position in the amino acid sequence of SEQ ID NO:1 and the amino acid residue existing at the same position brings about similar effects for a specific function of the protease.

[0016] Described specifically,

(a) the amino acid residue at position 84 of SEQ ID NO:1 is a lysine residue. By employing the above-described method, the amino acid residue at the position corresponding thereto can be identified as the lysine residue at position 83 of SEQ ID NO:3. This amino acid residue is preferably arginine.

(b) Although the amino acid residue at position 104 of SEQ ID NO:1 is a leucine residue, this amino acid residue

or an amino acid residue corresponding thereto is preferably a proline residue.

(c) Although the amino acid residue at position 256 of SEQ ID NO:1 is a methionine residue, particularly preferred as this amino acid residue is an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue.

(d) Although the amino acid residue at position 369 of SEQ ID NO:1 is an aspartic acid residue, this amino acid residue or amino acid residue corresponding thereto is preferably an asparagine residue.

(e) Although the amino acid residue at position 66 or 264 of SEQ ID NO:1 is an asparagine residue, this amino acid residue is preferably a glutamine, aspartic acid, serine, glutamic acid, alanine, threonine, leucine, methionine, cysteine, valine, glycine or isoleucine residue, with an aspartic acid, serine or glutamic acid residue being particularly preferred. More preferred is the case wherein the amino acid residue at position 66 is an aspartic acid residue and that at position 264 is a serine residue.

(f) Although the amino acid residue at each of positions 57, 101 to 106, 136, 193 and 342 of SEQ ID NO:1 is a glycine residue, this amino acid residue is preferably a lysine, serine, glutamine, phenylalanine, valine, arginine, tyrosine, leucine, isoleucine, threonine, methionine, cysteine, tryptophan, aspartic acid, glutamic acid, histidine, proline or alanine residue. Particularly preferred is the case wherein the amino acid residue at position 57, 136, 193 or 342 is an alanine residue, or that at position 103 is an arginine residue.

(g) Although the amino acid residue at position 46 or 205 of SEQ ID NO:1 is a phenylalanine residue, this amino acid residue is preferably a tyrosine, tryptophan, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, lysine, glutamine, methionine or cysteine residue. Particularly preferred is the case wherein the amino acid residue at position 46 is a leucine residue.

(h) Although the amino acid residue at position 54, 119, 138, 148 or 195 of SEQ ID NO:1 is a tyrosine residue, this amino acid residue is preferably a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, histidine, serine, glutamine, methionine, glycine, aspartic acid, proline, lysine, arginine or cysteine residue. Particularly preferred is the case wherein the amino acid residue at position 195 is an alanine, aspartic acid, glutamic acid, glutamine, valine, tryptophan, glycine, lysine, threonine, methionine, cysteine, phenylalanine, proline, serine, arginine, asparagine or histidine residue.

(i) Although the amino acid residue at position 247 of SEQ ID NO:1 is a lysine residue, this amino acid residue is preferably a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, glutamine, methionine or cysteine residue. As the amino acid residue at position 247, an arginine or threonine residue is particularly preferred.

(j) Although the amino acid residue at position 124 of SEQ ID NO:1 is an arginine residue, this amino acid residue is preferably an alanine or lysine residue.

(k) Although the amino acid residue at position 107 of SEQ ID NO:1 is a leucine residue, this amino acid residue is preferably a lysine, arginine, alanine or serine residue, with a lysine residue being particularly preferred.

(l) Although the amino acid residue at position 257 of SEQ ID NO:1 is an alanine residue, this amino acid residue is preferably a valine or isoleucine residue, with a valine residue being particularly preferred.

[0017] With regards to "another alkali protease" which is preferred among the above-exemplified ones, positions corresponding to (a) to (d) and (e) to (l) of the amino acid sequence (SEQ ID NO:1) of Protease KP43 and specific examples of an amino acid residue are shown below (Table 1-a, Table 1-b).

Table 1-a

Position	Proteases						
	TS43 SEQ ID NO:1	9860 SEQ ID NO:2	E-1 SEQ ID NO:3	Ya SEQ ID NO:4	SD-521 SEQ ID NO:5	A-1 SEQ ID NO:6	A-2 SEQ ID NO:7
(a)	84Lys	84Lys	83Lys	83Lys	83Lys	84Lys	83Lys
(b)	104Leu	104Leu	103Leu	103Leu	103Leu	104Leu	103Leu
(c)	256Met	256Met	255Met	255Met	255Met	256Met	255Met
(d)	369Asp	369Asp	368Asp	368Asp	368Asp	369Asp	368Asp

Table 1-b

Position	Proteases						
	TS43 SEQ ID NO:1	9860 SEQ ID NO:2	E-1 SEQ ID NO:3	Ya SEQ ID NO:4	SD-521 SEQ ID NO:5	A-1 SEQ ID NO:6	A-2 SEQ ID NO:7
(e)	66Asn 264Asn	66Asn 264Asn	66Asn 263Asn	66Asn 263Asn	66Asn 263Asn	66Asn 264Asn	66Asn 263Asn
(f)	57Gly 101Gly 102Gly 103Gly 105Gly 106Gly 136Gly 193Gly 342Gly	57Gly 101Ser 102Gly 103Gly 105Gly 106Gly 136Gly 193Gly 342Gly	56Gly 100Ser 101Gly 102Gly 104Gly 105Gly 135Gly 192Gly 341Gly	56Gly 100Ser 101Gly 102Gly 104Gly 105Gly 135Gly 192Gly 341Gly	56Gly 100Ser 101Gly 102Gly 104Gly 105Gly 135Gly 192Gly 341Gly	57Gly 101Asn 102Gly 103Gly 105Gly 106Gly 136Gly 193Gly 342Gly	56Gly 100Gly 101Gly 102Gly 104Gly 105Gly 135Gly 192Gly 341Gly
(g)	46Phe 205Phe	46Phe 205Phe	46Phe 204Phe	46Phe 204Phe	46Phe 204Phe	46Phe 205Phe	46Phe 204Phe
(h)	195Tyr	195Tyr	194Ile	194Ile	194Leu	195Tyr	194Tyr
(i)	247Lys	247Lys	246Lys	246Lys	246Lys	247Lys	246Lys
(j)	124Arg	124Arg	123Arg	123Arg	123Arg	124Arg	123Arg
(k)	107Leu	107Leu	106Leu	106Leu	106Leu	107Leu	106Leu
(l)	257Ala	257Ala	256Ala	256Ala	256Ala	257Ala	256Ala

[0018] In the alkaline proteases of the present invention, deletion of an amino acid residue or selection in (a) to (d) or (e) to (l) may be conducted at two or more positions simultaneously.

[0019] When the alkaline protease of the present invention is a variant, the "protease having an amino acid sequence represented by SEQ ID NO:1" or the above-exemplified "another alkaline protease" serves as an alkaline protease prior to mutation (which may be called "parent alkaline protease"). By introducing mutation to a desired site of this parent alkaline protease, the alkaline protease of the present invention is available. For example, it is available by deleting or substituting, with another amino acid residue, the amino acid residue at a position selected from the above-described (a) to (d) and (e) to (l) of the amino acid sequence of SEQ ID NO:1 of Protease KP43 or at the corresponding position of the amino acid sequence of another alkaline protease, more specifically, amino acid sequence represented by SEQ ID NOS:2 to 7.

[0020] The alkaline protease of the present invention can be obtained, for example, by introducing mutation to a cloned gene encoding a parent alkaline protease, transforming a proper host by using the resulting mutated gene and then culturing the recombinant host. Cloning of the gene for encoding a parent alkaline protease may be carried out using an ordinary gene recombination technique, for example, in accordance with the process as described in WO99/18218, JP901128 or WO98/56927.

[0021] For mutation of a gene encoding a parent alkaline protease, either one of random mutation or site-specific mutation which is prevalent now can be adopted. More specifically, mutation can be effected using, for example, "Site-Directed Mutagenesis System Mutan-Super Express Kit" of Takara Shuzo Co., Ltd. By using recombinant PCR (polymerase chain reaction) as described in "PCR protocols" (Academic Press, New York, 1990), a desired sequence of a gene can be replaced with a sequence of another gene corresponding to the desired sequence.

[0022] For production of the protease variant of the present invention by using the resulting mutated gene, usable is, for example, the following process. A DNA encoding the protease variant of the present invention is stably amplified by linking the mutated gene with a DNA vector capable of amplifying it stably or by introducing the mutated gene onto a chromosomal DNA capable of maintaining it stably and then, the gene is introduced into a host permitting stable and

efficient expression of the gene, whereby the variant protease is produced. Hosts satisfying the above-described conditions include microorganisms belonging to *Bacillus* sp., *Escherichia coli*, mold, yeast and *Actinomyces*.

[0023] The alkaline protease of the present invention thus obtained has stable protease activity in an alkaline region, is free from the inhibition of caseinolytic activity by higher fatty acids, and has a molecular weight, as determined by SDS-PAGE, $43,000 \pm 2,000$. For example, the protease variant available from, as a parent strain, the protease having an amino acid sequence of SEQ ID NO:1 has the below-described physicochemical properties.

(i) Acting pH range

[0024] It acts in a wide pH range of from 4 to 13 and exhibits at least 80% of the optimum pH active value at pH 6 to 12.

(ii) Stable pH range

[0025] It is stable within a pH range of 6 to 11 under the treating conditions at 40°C for 30 minutes.

(iii) Influence of fatty acids

[0026] Its caseinolytic activity is not inhibited by oleic acid.

[0027] Such proteases of the present invention have excellent specific activity, oxidant resistance and detergency and are therefore useful as an enzyme to be incorporated in various detergent compositions. Particularly, the proteases wherein the amino acid residue at position (a) to (d) of SEQ ID NO:1 or at a position corresponding thereto has been deleted or specified are superior in detergency. Among them, those having, as the amino acid residue at (c) position 256 or at a position corresponding thereto, an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue have both high specific activity and strong oxidant resistance. The proteases wherein the amino acid residue at position (e) to (l) of SEQ ID NO:1 or at a position corresponding thereto has been deleted or specified have particularly excellent specific activity.

[0028] The above-described protease may be added to the detergent composition of the present invention in an amount sufficient to permit exhibition of its activity. Although 0.1 to 5000 P.U. can be added per 1 kg of the detergent composition, 1000 P.U. or less, preferably 500 P.U. is added in consideration of economy.

[0029] To the detergent composition of the present invention, various enzymes can be used in combination with the alkaline protease of the present invention. Examples include hydrolases, oxidases, reductases, transferases, lyases, isomerases, ligases and synthetases. Of these, proteases, cellulases, lipases, keratinases, esterases, cutinases, amylases, pullulanases, pectinases, mannases, glucosidases, glucanases, cholesterol oxidases, peroxidases, laccases and proteases other than the alkaline protease used in the present invention are preferred.

[0030] Proteases include commercially available Alcalase, Esperase, Savinase and Everlase (each, product of Novo Nordisk), Properase and Purafect (each, product of Genencor International Inc.), and KAP (Kao Corp). Cellulases include Cellzyme and Carezyme (each, product of Novo Nordisk), KAC (Kao Corp.) and alkaline cellulase produced by *Bacillus* sp. strain KSM-S237 as described in Japanese Patent Application Laid-Open No. Hei 10-313859. Amylases include Termamyl and Duramyl (each, product of Novo Nordisk), Purastar (Genencor International Inc.), and KAM (Kao Corp.). Lipases include Lipolase and Liporase Ultra (each, product of Novo Nordisk). The above-exemplified enzyme may be incorporated in an amount of 0.001 to 10%, preferably 0.03 to 5%.

[0031] A surfactant may be incorporated in an amount of 0.5 to 60 wt.% (which will hereinafter be called "%", simply) in the detergent composition. To a powdery detergent composition and a liquid detergent composition, addition of 10 to 45% and 20 to 50% are preferred, respectively. When the detergent composition of the present invention is a bleaching detergent or automatic dishwasher detergent, the surfactant may usually be added in an amount of 1 to 10%, preferably 1 to 5%.

[0032] A divalent metal ion scavenger may be added in an amount of 0.01 to 50%, with 5 to 40% being preferred.

[0033] An alkali agent and inorganic salt may be added in an amount of 0.01 to 80%, preferably 1 to 40%.

[0034] An antisoil redeposition agent may be added in an amount of 0.001 to 10%, preferably 1 to 5%.

[0035] A bleaching agent (ex. hydrogen peroxide or percarbonate) is added preferably in an amount of 1 to 10%. Upon use of the bleaching agent, 0.01 to 10% of a bleaching activator can be added.

[0036] As a fluorescent brightener, biphenyl type ones (such as "Tinopal CBS-X") and stilbene type ones (such as DM fluorescent dye) can be used. It is added preferably in an amount of 0.001 to 2%.

[0037] The detergent composition of the present invention can be prepared in a conventional manner by using the alkaline protease obtained by the above-described process and the above-described known detergent components in combination. The detergent form can be selected according to the using purpose. Examples include liquid, powder and granule.

[0038] When the alkaline protease of the present invention is added to a powdery detergent composition, it is pre-

ferred to prepare detergent particles in advance and then mix therein the alkaline protease granules in accordance with the process as described in Japanese Patent Application Laid-Open No. Sho 62-25790 in order to avoid the contact of workers or end users with the enzyme upon preparation or use of the detergent or to prevent heat-induced deactivation or decomposition of the enzyme.

[0039] The detergent composition of the present invention thus available is usable as a laundry detergent, bleaching detergent, automatic dishwasher detergent, pipe cleaner and artificial tooth cleaner. Use as a laundry detergent, bleaching detergent or automatic dishwasher detergent is particularly preferred.

Example 1

[0040] Mutation was introduced at random into a protease structural gene of about 2.0 kb including a termination codon by the following manner. First, PCR was conducted using a primer capable of amplifying this 2.0kb. A PCR master mix contained 5 ng of a template DNA, 20 pmol of a phosphorylated primer, 20 nmol of each dNTP, 1 μ mol of Tris/HCl (pH 8.3), 5 μ mol of KCl, 0.15 μ mol of $MgCl_2$ and 2.5U TaqDNA polymerase, and its total amount was adjusted to 100 μ L. After modification of the template by allowing it to stand at 94°C for 5 minutes, PCR was performed for 30 cycles, each cycle consisting of treatment at 94°C for 1 min, at 55°C for 1 min and at 72°C for 1.5 min. The PCR product was purified by "PCR product purification Kit" (product of Boeringer Mannheim), followed by elution in 100 μ L of sterile water. With 1 μ L of the eluate, second PCR was conducted under conditions similar to those of the first PCR except for the template DNA. After completion of the second PCR, the PCR product was purified in a similar manner to the first PCR, followed by elution in 100 μ L of sterile water.

[0041] The amplified DNA fragment was integrated in a vector by polymerase reaction using "LATAq" produced by Takara Shuzo Co., Ltd. Described specifically, after addition of 5 μ L of a buffer for LATAq (a 10-fold concentrate), 8 μ L of a dNTP solution and 0.5 μ L of LATAq DNA polymerase, and as a template, 20 ng of plasmid pHA64TS (having a protease structural gene linked with an expression vector pHA64) to 35 μ L of the purified eluate, the total amount was adjusted to 50 μ L. PCR reaction of the resulting liquid was carried out for 30 cycles, each consisting of treatment at 94°C for 1 min, 55°C for 1 min and 72°C for 4 min. By the subsequent ethanol precipitation, the PCR product was collected. This PCR product had a shape of a plasmid having a nick at the 5' prime end of the primer. Ligase reaction by T4 ligase (product of Takara Shuzo Co., Ltd.) was conducted to link this nick portion.

[0042] By using 10 μ L of this ligase reaction mixture, transformation of the *Bacillus subtilis* strain ISW1214 was conducted, whereby about 4×10^5 transformants were obtained. The resulting transformants of the strain ISW1214 were cultured on a skin-milk-containing medium (containing 1% skim milk, 1% bacto-trypton, 1% sodium chloride, 0.5% yeast extract, 1.5% agar and 7.5 μ g/ml of tetracycline) and halo formation, which was presumed to reflect the protease secretion amount, was observed.

Example 2: Purification of an enzyme

[0043] The protease active fraction was prepared in the following manner. The transformants obtained in Example 1 was cultured at 30°C for 60 hours on a medium A (3% polypeptone S (product of Nippon Pharmaceutical), 0.5% yeast extract, 1% fish meat extract (product of Wako Pure Chemical Industries, Ltd.), 0.15% dipotassium phosphate, 0.02% magnesium sulfate 7 hydrate, 4% maltose and 7.5 μ g/ml of tetracycline). The supernatant of the thus-obtained cultured medium was added with ammonium sulfate to give 90% saturation, whereby salting-out of protein was caused. The sample obtained by salting-out was dissolved in a 10 mM tris HCl buffer (pH 7.5) containing 2 mM of calcium chloride. The resulting solution was dialyzed overnight against the same buffer by using a dialysis membrane. The fraction in the dialysis membrane was applied to DEAE Bio-Gel A (product of Bio-Rad Laboratories) equilibrated with a 10 mM tris HCl buffer (pH 7.5) containing 2 mM calcium chloride to collect the protease active fraction not adsorbed to the ion-exchanger. This active fraction was applied further to "SP-Toyopearl 550W" (product of Tosoh Corp.) equilibrated with the same buffer, followed by elution with a 0 to 50 mM sodium chloride solution, whereby a protease active fraction was obtained. The resulting fraction was analyzed by SDS-PAGE electrophoresis to confirm that the protease was obtained as substantially uniform protein. The protein concentration was measured in accordance with the method of Lowry, et al. (J. Biol. Chem. **193**, 265-275(1981)) by using bovine serum albumin (product of Bio-Rad Laboratories) as a standard.

Example 3: Measuring method of protease activity

(1) Synthetic substrate assay

[0044] A decomposition rate was measured using a synthetic peptide made of Glt-Ala-Ala-Pro-Leu(A-A-P-L) as a substrate. Described specifically, a 50 mM borate/KCl buffer (pH 10.5) containing each enzyme to be evaluated and

3 mM of Glt-A-A-P-L-pNA (product of Peptide Institute, Inc) was kept at 30°C for 10 minutes and then, an absorbance at 420 nm was periodically measured. The peptide hydrolyzing activity was determined from an increasing ratio of the absorbance at 420 nm per unit hour. The protein was determined using a protein assay kit of Bio-Rad Laboratories.

(2) Natural substrate assay

[0045] After 1.0 mL of a 50 mM borate buffer (pH 10) containing 1% (w/v) of casein was kept at 30°C for 5 minutes, 0.1 mL of an enzyme solution was added and reaction was conducted for 15 minutes. To the reaction mixture, 2.0 mL of a reaction-stopping solution (0.11M trichloroacetic acid - 0.22M sodium acetate - 0.33M acetic acid) was added. The resulting mixture was allowed to stand at room temperature for 30 minutes and the filtered. The acid soluble protein in the filtrate was quantitatively determined by the modified method of Lowry, et al. Described specifically, after addition of 2.5 mL of an alkaline copper solution [1% potassium sodium tartrate : 1% copper sulfate : 1% sodium carbonate = 1:1:100] to the filtrate, the resulting solution was allowed to stand at room temperature for 10 minutes. Then, 0.25 mL of a diluted phenol solution (a phenol reagent (product of Kanto Kagaku) diluted 2-fold with ion exchange water) was added. After the resulting mixture was kept at 30°C for 30 minutes, absorbance at 660 nm was measured. One enzyme unit was designated as a quantity of the enzyme for liberating the acid soluble protein hydrolysis product corresponding to 1 mmol of tyrosine for 1 min in the above-described reaction.

Example 4

(1) Preparation of granular detergent

[0046] Detergency of the detergent as described in Example 3 of WO99/29830 was evaluated. Described specifically, 465 kg of water was poured in a mixing tank of 1 m³ equipped with a stirring blade. After its water temperature reached 55°C, 48 kg of a 50% (w/v) aqueous solution of sodium dodecylbenzenesulfonate and 135 kg of a 40% (w/v) aqueous solution of sodium polyacrylate were added. After stirring for 15 minutes, 120 kg of sodium carbonate, 60 kg of sodium sulfate, 9 kg of sodium sulfite and 3 kg of a fluorescent dye were added. After stirring for further 15 minutes, 300 kg of zeolite was added. The mixture was stirred for 30 minutes to yield a uniform slurry (the slurry had a water content of 50 wt.%). By spraying this slurry from a pressure spraying nozzle disposed in the vicinity of the top of a spray drying tower, base granules were obtained (a high temperature gas was fed to the spray drying tower at 225°C from the tower bottom and discharged from the tower top at 105°C).

[0047] Then, 15 parts by weight of a nonionic surfactant, 15 parts by weight of a 50 wt.% aqueous solution of sodium dodecylbenzenesulfonate and 1 part by weight of polyethylene glycol were mixed under heating to 70°C, whereby a mixture was obtained. In a Loedige mixer (product of Matsuzaka Giken Co., Ltd., capacity: 20L, equipped with a jacket), 100 parts by weight of the base granules obtained above were charged and stirring by a main shaft (150 rpm) and chopper (4000 rpm) was started. Warm water of 75°C was caused to flow in the jacket at 10 L/min, the mixture was charged therein in 3 minutes, and then stirring was conducted for 5 minutes. The surface of the detergent particles were covered with 10 parts by weight of crystalline aluminosilicate, whereby the final product of the granular detergent was obtained.

[Raw materials used]

Aqueous solution of sodium dodecylbenzenesulfonate: "Neopelex F65" (product of Kao Corp.)

[0048] Nonionic surfactant: "Emulgen 108KM" (product of Kao) added with 8.5 moles, on average, of ethylene oxide
Aqueous solution of sodium polyacrylate: having an average molecular weight of 10000 (prepared in accordance with the process as described in Example of Japanese Patent Publication No. Hei 2-24283)

Sodium carbonate: dense ash (product of Central Glass Co., Ltd.)

Zeolite: "Zeolite 4A" having an average particle size of 3.5 µm (product of Tosoh Corp)

Polyethylene glycol: "K-PEG6000" (average molecular weight of 8500, product of Kao Corp.)

Fluorescent dye: "Tinopai CBS-X" (product of Ciba Geigy)

(2) Preparation of granulated protease

[0049] From the alkaline proteases of the present invention and a purified preparation of a parent alkaline protease, granulated protease was prepared based on the process as described in Japanese Patent Application Laid-Open No. Sho 62-257990 (6P.U./g)

(3) Measurement of detergency

[0050] In 1L of an aqueous calcium solution (71.2 mg calcium carbonate/1L) adjusted to 20°C, 0.67 g of each of the detergent compositions as shown in Table 2 was dissolved. With the resulting solution, a test cloth ("EMPA117" - prepared by Swiss Federal Laboratories for Materials Testing and Research, blood/milk/carbon) cut into a piece of 6 × 6 cm was washed using a Terg-O-tometer (product of Ueshima Seisakusho) at 20°C and 100 rpm for 10 minutes. After rinsing and drying, the brightness was measured using a spectrophotometer ("CM3500d", product of MINOLTA). A detergency was calculated based on the below-described equation. The results are shown in Table 2.

$$\text{Detergency (\%)} = \frac{\text{Brightness of the test fabric after washing} - \text{that before washing}}{\text{Brightness of the test fabric before soiling} - \text{that before washing}} \times 100$$

[0051] Measuring results of the detergency of the protease variants obtained in Example 1 are shown in FIG. 1. The alkaline protease variants of the present invention each exhibited superior detergency to wild type enzymes to which mutation had not been introduced.

Table 2

Table 2									
			Invention products					Comparative products	
			1	2	3	4	5	1	2
Parts by weight	Granulated alkaline proteases of this invention	K84R	0.5	0.5	0.5	0.5	0.5		
		L104P							
		M256S							
		M256A							
	D369N								
	Granulated parent alkaline protease							0.5	
	Granular detergent		99.5						100
Detergency (%)			38	38	36	36	34	31	23

Example 5

[0052] Measuring results, in accordance with the synthetic substrate assay or natural substrate assay, of protease activity of the protease variants obtained in Example 1 (the proteases modified at 195-position and 256-position amino acid residues, respectively was measured by the latter assay, while the other proteases were measured by the former assay) are shown in FIG. 2. The alkaline protease variants of the present invention exhibited high specific activity.

Example 6

[0053] In 2 mL of a 100 mM borate buffer (pH 10.5) containing 3% of aqueous hydrogen peroxide, a 50 µl portion of each of the protease variants obtained by purification in Example 1 was added. The resulting mixture was allowed to stand at 30°C for 30 minutes. After addition of an adequate amount of catalase (product of Boehringer Mannheim) to remove excess hydrogen peroxide, the residual protease activity was measured by the synthetic substrate assay. In FIG. 3, the residual activity after treatment with aqueous hydrogen peroxide is shown relative to the activity before treatment set at 100%.

[0054] The alkaline protease variants of the present invention exhibited higher oxidant resistance than the parent alkaline protease.

[0055] The present invention makes it possible to provide alkaline proteases having activity even under a high concentration of fatty acids, having high specific activity, oxidant resistance and detergency, and being useful as an enzyme to be incorporated in a detergent.

SEQUENCE LISTING

<110> KAO CORPORATION

5 <120> Alkaline protease

<130> F 2935 EP

10 <150> JP P2000-355166

<151> 2000-11-22

<150> JP P2001-114048

<151> 2001-4-12

15 <160> 7

<170> PatentIn Ver. 2.1

<210> 1

20 <211> 434

<212> PRT

<213> Bacillus sp.

<400> 1

25 Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Ser Ser
1 5 10 15Tyr Gly Leu Tyr Gly Gln Gly Gln Ile Val Ala Val Ala Asp Thr Gly
20 25 3030 Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
35 40 45Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp
50 55 6035 Thr Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Gly
65 70 75 8040 Ser Thr Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser
85 90 95Ile Met Asp Ser Gly Gly Gly Leu Gly Gly Leu Pro Ser Asn Leu Gln
100 105 11045 Thr Leu Phe Ser Gln Ala Tyr Ser Ala Gly Ala Arg Ile His Thr Asn
115 120 125Ser Trp Gly Ala Ala Val Asn Gly Ala Tyr Thr Thr Asp Ser Arg Asn
130 135 14050 Val Asp Asp Tyr Val Arg Lys Asn Asp Met Thr Ile Leu Phe Ala Ala
145 150 155 16055 Gly Asn Glu Gly Pro Asn Gly Gly Thr Ile Ser Ala Pro Gly Thr Ala
165 170 175

EP 1 209 233 A2

5 Lys Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Leu Arg Pro Ser Phe
180 185 190

Gly Ser Tyr Ala Asp Asn Ile Asn His Val Ala Gln Phe Ser Ser Arg
195 200 205

10 Gly Pro Thr Lys Asp Gly Arg Ile Lys Pro Asp Val Met Ala Pro Gly
210 215 220

Thr Phe Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe
225 230 235 240

15 Trp Ala Asn His Asp Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met
245 250 255

Ala Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe
260 265 270

20 Val Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Leu Lys Ala Ala
275 280 285

Leu Ile Ala Gly Ala Ala Asp Ile Gly Leu Gly Tyr Pro Asn Gly Asn
290 295 300

25 Gln Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Tyr
305 310 315 320

30 Val Asn Glu Ser Ser Ser Leu Ser Thr Ser Gln Lys Ala Thr Tyr Ser
325 330 335

Phe Thr Ala Thr Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Ser
340 345 350

35 Asp Ala Pro Ala Ser Thr Thr Ala Ser Val Thr Leu Val Asn Asp Leu
355 360 365

Asp Leu Val Ile Thr Ala Pro Asn Gly Thr Gln Tyr Val Gly Asn Asp
370 375 380

40 Phe Thr Ser Pro Tyr Asn Asp Asn Trp Asp Gly Arg Asn Asn Val Glu
385 390 395 400

45 Asn Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Thr Ile Glu Val
405 410 415

Gln Ala Tyr Asn Val Pro Val Gly Pro Gln Thr Phe Ser Leu Ala Ile
420 425 430

50 Val Asn

<210> 2
<211> 434
<212> PRT
55 <213> Bacillus sp.

EP 1 209 233 A2

<400> 2

5	Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Ser Ser	1	5	10	15
	Tyr Gly Leu Tyr Gly Gln Gly Gln Ile Val Ala Val Ala Asp Thr Gly	20	25	30	
10	Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly	35	40	45	
	Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp	50	55	60	
15	Thr Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Gly	65	70	75	80
	Ala Thr Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser	85	90	95	
20	Ile Met Asp Ser Ser Gly Gly Leu Gly Gly Leu Pro Ser Asn Leu Gln	100	105	110	
	Thr Leu Phe Ser Gln Ala Phe Ser Ala Gly Ala Arg Ile His Thr Asn	115	120	125	
25	Ser Trp Gly Ala Ala Val Asn Gly Ala Tyr Thr Thr Asp Ser Arg Asn	130	135	140	
30	Val Asp Asp Tyr Val Arg Lys Asn Asp Met Thr Ile Leu Phe Ala Ala	145	150	155	160
	Gly Asn Glu Gly Pro Asn Gly Gly Thr Ile Ser Ala Pro Gly Thr Ala	165	170	175	
35	Lys Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Leu Arg Pro Ser Phe	180	185	190	
	Gly Ser Tyr Ala Asp Asn Ile Asn His Val Ala Gln Phe Ser Ser Arg	195	200	205	
40	Gly Pro Thr Lys Asp Gly Arg Ile Lys Pro Asp Val Met Ala Pro Gly	210	215	220	
45	Thr Tyr Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe	225	230	235	240
	Trp Ala Asn His Asp Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met	245	250	255	
50	Ala Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe	260	265	270	
	Val Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Leu Lys Ala Ala	275	280	285	
55					

EP 1 209 233 A2

5 Leu Ile Ala Gly Ala Ala Asp Val Gly Leu Gly Tyr Pro Asn Gly Asn
 290 295 300
 Gln Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Tyr
 305 310 315 320
 10 Val Asn Glu Ser Ser Ala Leu Ser Thr Ser Gln Lys Ala Thr Tyr Thr
 325 330 335
 Phe Thr Ala Thr Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Ser
 340 345 350
 15 Asp Ala Pro Ala Ser Thr Thr Ala Ser Val Thr Leu Val Asn Asp Leu
 355 360 365
 Asp Leu Val Ile Thr Ala Pro Asn Gly Thr Arg Tyr Val Gly Asn Asp
 370 375 380
 20 Phe Ser Ala Pro Phe Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu
 385 390 395 400
 Asn Val Phe Ile Asn Ser Pro Gln Ser Gly Thr Tyr Thr Ile Glu Val
 405 410 415
 25 Gln Ala Tyr Asn Val Pro Val Gly Pro Gln Asn Phe Ser Leu Ala Ile
 420 425 430
 30 Val Asn
 <210> 3
 <211> 433
 <212> PRT
 <213> Bacillus sp.
 35 <400> 3
 Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Asn Asn
 1 5 10 15
 40 Tyr Gly Leu Tyr Gly Gln Gly Gln Val Val Ala Val Ala Asp Thr Gly
 20 25 30
 Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
 35 40 45
 45 Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp
 50 55 60
 Pro Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Ala
 65 70 75 80
 50 Leu Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser Ile
 85 90 95
 55 Met Asp Ser Ser Gly Gly Leu Gly Gly Leu Pro Ser Asn Leu Asn Thr

EP 1 209 233 A2

	100	105	110
5	Leu Phe Ser Gln Ala Trp Asn Ala Gly Ala Arg Ile His Thr Asn Ser 115 120 125		
	Trp Gly Ala Pro Val Asn Gly Ala Tyr Thr Ala Asn Ser Arg Gln Val 130 135 140		
10	Asp Glu Tyr Val Arg Asn Asn Asp Met Thr Val Leu Phe Ala Ala Gly 145 150 155 160		
	Asn Glu Gly Pro Asn Ser Gly Thr Ile Ser Ala Pro Gly Thr Ala Lys 165 170 175		
15	Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Tyr Arg Pro Ser Phe Gly 180 185 190		
	Ser Ile Ala Asp Asn Pro Asn His Ile Ala Gln Phe Ser Ser Arg Gly 195 200 205		
20	Ala Thr Arg Asp Gly Arg Ile Lys Pro Asp Val Thr Ala Pro Gly Thr 210 215 220		
	Phe Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe Trp 225 230 235 240		
25	Ala Asn Tyr Asn Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met Ala 245 250 255		
	Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe Ile 260 265 270		
30	Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Ile Lys Ala Ala Leu 275 280 285		
	Ile Ala Gly Ala Thr Asp Val Gly Leu Gly Tyr Pro Ser Gly Asp Gln 290 295 300		
35	Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Tyr Val 305 310 315 320		
	Asn Glu Ala Thr Ala Leu Thr Thr Gly Gln Lys Ala Thr Tyr Ser Phe 325 330 335		
40	Gln Thr Gln Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Thr Asp 340 345 350		
	Ala Pro Gly Ser Thr Thr Ala Ser Tyr Thr Leu Val Asn Asp Leu Asp 355 360 365		
45	Leu Val Ile Thr Ala Pro Asn Gly Gln Lys Tyr Val Gly Asn Asp Phe 370 375 380		
	Ser Tyr Pro Tyr Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu Asn 385 390 395 400		

EP 1 209 233 A2

5 Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Thr Ile Glu Val Gln
405 410 415

Ala Tyr Asn Val Pro Ser Gly Pro Gln Arg Phe Ser Leu Ala Ile Val
420 425 430

10 His

<210> 4
<211> 433
<212> PRT
<213> Bacillus sp.

15 <400> 4
Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Asn Asn
1 5 10 15

20 Tyr Gly Leu Tyr Gly Gln Gly Gln Val Val Ala Val Ala Asp Thr Gly
20 25 30

Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
35 40 45

25 Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Ser Asp
50 55 60

Pro Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Ala
65 70 75 80

30 Leu Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser Ile
85 90 95

Met Asp Ser Ser Gly Gly Leu Gly Gly Leu Pro Ser Asn Leu Asn Thr
100 105 110

35 Leu Phe Ser Gln Ala Trp Asn Ala Gly Ala Arg Ile His Thr Asn Ser
115 120 125

40 Trp Gly Ala Pro Val Asn Gly Ala Tyr Thr Ala Asn Ser Arg Gln Val
130 135 140

Asp Glu Tyr Val Arg Asn Asn Asp Met Thr Val Leu Phe Ala Ala Gly
145 150 155 160

45 Asn Glu Gly Pro Asn Ser Gly Thr Ile Ser Ala Pro Gly Thr Ala Lys
165 170 175

Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Tyr Arg Pro Ser Phe Gly
180 185 190

50 Ser Ile Ala Asp Asn Pro Asn His Ile Ala Gln Phe Ser Ser Arg Gly
195 200 205

Ala Thr Arg Asp Gly Arg Ile Lys Pro Asp Val Thr Ala Pro Gly Thr

55

EP 1 209 233 A2

	210	215	220
5	Phe Ile Leu Ser Ala Arg	Ser Ser Leu Ala	Pro Asp Ser Ser Phe Trp
	225	230	235 240
	Ala Asn Tyr Asn Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met Ala		
		245 250	255
10	Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe Ile		
		260 265	270
	Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Ile Lys Ala Ala Leu		
		275 280	285
15	Ile Ala Gly Ala Thr Asp Val Gly Leu Gly Tyr Pro Asn Gly Asp Gln		
		290 295	300
20	Gly Trp Gly Arg Val Thr Leu Asn Lys Ser Leu Asn Val Ala Tyr Val		
		305 310	315 320
	Asn Glu Ala Thr Ala Leu Ala Thr Gly Gln Lys Ala Thr Tyr Ser Phe		
		325 330	335
25	Gln Ala Gln Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Thr Asp		
		340 345	350
	Ala Pro Gly Ser Thr Thr Ala Ser Tyr Thr Leu Val Asn Asp Leu Asp		
		355 360	365
30	Leu Val Ile Thr Ala Pro Asn Gly Gln Lys Tyr Val Gly Asn Asp Phe		
		370 375	380
	Ser Tyr Pro Tyr Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu Asn		
		385 390	395 400
35	Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Ile Ile Glu Val Gln		
		405 410	415
40	Ala Tyr Asn Val Pro Ser Gly Pro Gln Arg Phe Ser Leu Ala Ile Val		
		420 425	430
	His		
45	<210> 5		
	<211> 433		
	<212> PRT		
	<213> Bacillus sp.		
	<400> 5		
50	Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Asn Asn		
	1 5 10 15		
	Tyr Gly Leu Tyr Gly Gln Gly Gln Val Val Ala Val Ala Asp Thr Gly		
		20 25 30	

55

EP 1 209 233 A2

Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
35 40 45

5 Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp
50 55 60

Pro Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Ala
65 70 75 80

10 Leu Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser Ile
85 90 95

Met Asp Ser Ser Gly Gly Leu Gly Gly Leu Pro Ser Asn Leu Asn Thr
100 105 110

15 Leu Phe Ser Gln Ala Trp Asn Ala Gly Ala Arg Ile His Thr Asn Ser
115 120 125

Trp Gly Ala Pro Val Asn Gly Ala Tyr Thr Ala Asn Ser Arg Gln Val
130 135 140

20 Asp Glu Tyr Val Arg Asn Asn Asp Met Thr Val Leu Phe Ala Ala Gly
145 150 155 160

25 Asn Glu Gly Pro Asn Ser Gly Thr Ile Ser Ala Pro Gly Thr Ala Lys
165 170 175

Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Tyr Arg Pro Ser Phe Gly
180 185 190

30 Ser Leu Ala Asp Asn Pro Asn His Ile Ala Gln Phe Ser Ser Arg Gly
195 200 205

Ala Thr Arg Asp Gly Arg Ile Lys Pro Asp Val Thr Ala Pro Gly Thr
210 215 220

35 Phe Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe Trp
225 230 235 240

Ala Asn Tyr Asn Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met Ala
245 250 255

40 Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe Ile
260 265 270

45 Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Ile Lys Ala Ala Leu
275 280 285

Ile Ala Gly Ala Thr Asp Val Gly Leu Gly Tyr Pro Ser Gly Asp Gln
290 295 300

50 Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Tyr Val
305 310 315 320

Asn Glu Ala Thr Ala Leu Ala Thr Gly Gln Lys Ala Thr Tyr Ser Phe

55

EP 1 209 233 A2

5 Gln Ala Gln Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Thr Asp
340 345 350

Ala Pro Gly Ser Thr Thr Ala Ser Tyr Thr Leu Val Asn Asp Leu Asp
355 360 365

10 Leu Val Ile Thr Ala Pro Asn Gly Gln Lys Tyr Val Gly Asn Asp Phe
370 375 380

Ser Tyr Pro Tyr Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu Asn
385 390 395 400

15 Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Thr Ile Glu Val Gln
405 410 415

20 Ala Tyr Asn Val Pro Ser Gly Pro Gln Arg Phe Ser Leu Ala Ile Val
420 425 430

His

<210> 6
<211> 434
<212> PRT
<213> Bacillus sp.

<400> 6

30 Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Ser Ser
1 5 10 15

Tyr Gly Leu Tyr Gly Gln Gly Gln Val Val Ala Val Ala Asp Thr Gly
20 25 30

35 Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
35 40 45

Lys Ile Thr Ala Ile Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp
50 55 60

40 Pro Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Gly
65 70 75 80

45 Thr Ser Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser
85 90 95

Val Met Asp Ser Asn Gly Gly Leu Gly Gly Leu Pro Ser Asn Val Ser
100 105 110

50 Thr Leu Phe Ser Gln Ala Tyr Ser Ala Gly Ala Arg Ile His Thr Asn
115 120 125

Ser Trp Gly Ala Pro Val Asn Gly Ala Tyr Thr Thr Asp Ser Arg Asn
130 135 140

EP 1 209 233 A2

Val Asp Asp Tyr Val Arg Lys Asn Asp Met Ala Val Leu Phe Ala Ala
145 150 155 160

5 Gly Asn Glu Gly Pro Asn Gly Gly Thr Ile Ser Ala Pro Gly Thr Ala
165 170 175

Lys Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Leu Arg Pro Ser Phe
180 185 190

10 Gly Ser Tyr Ala Asp Asn Ile Asn His Val Ala Gln Phe Ser Ser Arg
195 200 205

Gly Pro Thr Lys Asp Gly Arg Ile Lys Pro Asp Val Met Ala Pro Gly
15 210 215 220

Thr Phe Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe
225 230 235 240

20 Trp Ala Asn His Asp Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met
245 250 255

Ala Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe
260 265 270

25 Ile Lys Asn Arg Gly Ile Thr Pro Lys Pro Ser Leu Leu Lys Ala Ala
275 280 285

Leu Ile Ala Gly Ala Thr Asp Ile Gly Leu Gly Tyr Pro Ser Gly Asn
290 295 300

30 Gln Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Phe
305 310 315 320

Val Asn Glu Thr Ser Ser Leu Ser Thr Asn Gln Lys Ala Thr Tyr Ser
35 325 330 335

Phe Thr Ala Gln Ser Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Ser
340 345 350

40 Asp Ala Pro Ala Ser Thr Ser Ala Ser Val Thr Leu Val Asn Asp Leu
355 360 365

Asp Leu Val Ile Thr Ala Pro Asn Gly Thr Lys Tyr Val Gly Asn Asp
370 375 380

45 Phe Thr Ala Pro Tyr Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu
385 390 395 400

Asn Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Thr Val Glu Val
50 405 410 415

Gln Ala Tyr Asn Val Pro Gln Gly Pro Gln Ala Phe Ser Leu Ala Ile
420 425 430

55 Val Asn

EP 1 209 233 A2

5 <210> 7
 <211> 433
 <212> PRT
 <213> Bacillus sp.

 <400> 7
 10 Asn Asp Val Ala Arg Gly Ile Val Lys Ala Asp Val Ala Gln Asn Asn
 1 5 10 15
 Phe Gly Leu Tyr Gly Gln Gly Gln Ile Val Ala Val Ala Asp Thr Gly
 20 25 30
 15 Leu Asp Thr Gly Arg Asn Asp Ser Ser Met His Glu Ala Phe Arg Gly
 35 40 45
 Lys Ile Thr Ala Leu Tyr Ala Leu Gly Arg Thr Asn Asn Ala Asn Asp
 50 55 60
 20 Pro Asn Gly His Gly Thr His Val Ala Gly Ser Val Leu Gly Asn Ala
 65 70 75 80
 Thr Asn Lys Gly Met Ala Pro Gln Ala Asn Leu Val Phe Gln Ser Ile
 85 90 95
 25 Met Asp Ser Gly Gly Gly Leu Gly Gly Leu Pro Ala Asn Leu Gln Thr
 100 105 110
 30 Leu Phe Ser Gln Ala Tyr Ser Ala Gly Ala Arg Ile His Thr Asn Ser
 115 120 125
 Trp Gly Ala Pro Val Asn Gly Ala Tyr Thr Thr Asp Ser Arg Asn Val
 130 135 140
 35 Asp Asp Tyr Val Arg Lys Asn Asp Met Thr Ile Leu Phe Ala Ala Gly
 145 150 155 160
 Asn Glu Gly Pro Gly Ser Gly Thr Ile Ser Ala Pro Gly Thr Ala Lys
 165 170 175
 40 Asn Ala Ile Thr Val Gly Ala Thr Glu Asn Leu Arg Pro Ser Phe Gly
 180 185 190
 45 Ser Tyr Ala Asp Asn Ile Asn His Val Ala Gln Phe Ser Ser Arg Gly
 195 200 205
 Pro Thr Arg Asp Gly Arg Ile Lys Pro Asp Val Met Ala Pro Gly Thr
 210 215 220
 50 Tyr Ile Leu Ser Ala Arg Ser Ser Leu Ala Pro Asp Ser Ser Phe Trp
 225 230 235 240
 Ala Asn His Asp Ser Lys Tyr Ala Tyr Met Gly Gly Thr Ser Met Ala
 245 250 255

Thr Pro Ile Val Ala Gly Asn Val Ala Gln Leu Arg Glu His Phe Val
 260 265 270
 5 Lys Asn Arg Gly Val Thr Pro Lys Pro Ser Leu Leu Lys Ala Ala Leu
 275 280 285
 Ile Ala Gly Ala Ala Asp Val Gly Leu Gly Phe Pro Asn Gly Asn Gln
 290 295 300
 10 Gly Trp Gly Arg Val Thr Leu Asp Lys Ser Leu Asn Val Ala Phe Val
 305 310 315 320
 Asn Glu Thr Ser Pro Leu Ser Thr Ser Gln Lys Ala Thr Tyr Ser Phe
 325 330 335
 15 Thr Ala Gln Ala Gly Lys Pro Leu Lys Ile Ser Leu Val Trp Ser Asp
 340 345 350
 Ala Pro Gly Ser Thr Thr Ala Ser Leu Thr Leu Val Asn Asp Leu Asp
 355 360 365
 20 Leu Val Ile Thr Ala Pro Asn Gly Thr Lys Tyr Val Gly Asn Asp Phe
 370 375 380
 Thr Ala Pro Tyr Asp Asn Asn Trp Asp Gly Arg Asn Asn Val Glu Asn
 385 390 395 400
 25 Val Phe Ile Asn Ala Pro Gln Ser Gly Thr Tyr Thr Val Glu Val Gln
 405 410 415
 30 Ala Tyr Asn Val Pro Val Ser Pro Gln Thr Phe Ser Leu Ala Ile Val
 420 425 430
 35 His

Claims

- 40 1. An alkaline protease wherein an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from:

45 at position (a): an arginine residue,
 at position (b): a proline residue,
 at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue,
 and
 at position (d): an aspartic acid residue.

- 50 2. An alkaline protease having an amino acid sequence represented by SEQ ID NO:1 or having an amino acid sequence showing at least 60% homology therewith, wherein an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from:

55 at position (a): an arginine residue,
 at position (b): a proline residue,
 at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue,
 and

at position (d): an aspartic acid residue.

3. An alkaline protease wherein an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 of SEQ ID NO:1, or at a position corresponding thereto has been deleted or selected from::

at position (e): a glutamine, aspartic acid, serine, glutamic acid, alanine, threonine, leucine, methionine, cysteine, valine, glycine or isoleucine residue

at position (f): a lysine, serine, glutamine, phenylalanine, valine, arginine, tyrosine, leucine, isoleucine, threonine, methionine, cysteine, tryptophan, aspartic acid, glutamic acid, histidine, proline or alanine residue,

at position (g): a tyrosine, tryptophan, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, lysine, glutamine, methionine or cysteine residue,

at position (h): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, histidine, serine, lysine, glutamine, methionine, glycine, aspartic acid, proline, arginine or cysteine residue,

at position (i): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, glutamine, methionine or cysteine residue,

at position (j): an alanine or lysine residue,

at position (k): a lysine, arginine, alanine or serine residue, and

at position (l): a valine or isoleucine residue.

4. An alkaline protease having an amino acid sequence represented by SEQ ID NO:1 or having an amino acid sequence showing at least 60% homology therewith, wherein an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 has been deleted or selected from:

at position (e): a glutamine, aspartic acid, serine, glutamic acid, alanine, threonine, leucine, methionine, cysteine, valine, glycine or isoleucine residue

at position (f): a lysine, serine, glutamine, phenylalanine, valine, arginine, tyrosine, leucine, isoleucine, threonine, methionine, cysteine, tryptophan, aspartic acid, glutamic acid, histidine, proline or alanine residue,

at position (g): a tyrosine, tryptophan, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, lysine, glutamine, methionine or cysteine residue,

at position (h): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, histidine, serine, lysine, glutamine, methionine, glycine, aspartic acid, proline, arginine or cysteine residue,

at position (i): a tryptophan, phenylalanine, alanine, asparagine, glutamic acid, threonine, valine, leucine, isoleucine, histidine, serine, glutamine, methionine or cysteine residue,

at position (j): an alanine or lysine residue,

at position (k): a lysine, arginine, alanine or serine residue, and

at position (l): a valine or isoleucine residue.

5. An alkaline protease according to claim 2 or 4, wherein the amino acid sequence represented by SEQ ID NO:1 or amino acid sequence showing at least 60% homology therewith is an amino acid sequence selected from SEQ ID NOS: 2 to 7.

6. A gene encoding an alkaline protease as claimed in any one of claims 1 to 5.

7. A recombinant vector comprising a gene as claimed in claim 6.

8. A transformant comprising a recombinant vector as claimed in claim 7.

9. A transformant according to claim 8, wherein a microorganism is used as a host.

10. A detergent composition comprising an alkaline protease as claimed in any one of claims 1 to 5.

FIG. 1




FIG. 2






FIG. 3



THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 1 209 233 A3

EUROPEAN PATENT APPLICATION

(12)

(88) Date of publication A3:
15.10.2003 Bulletin 2003/42

(51) Int Cl.7: C12N 15/57, C12N 9/54,
C12N 1/21, C11D 3/386

(43) Date of publication A2:
29.05.2002 Bulletin 2002/22

(21) Application number: 01127851.2

(22) Date of filing: 22.11.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.11.2000 JP 2000355166
12.04.2001 JP 2001114048

(71) Applicant: Kao Corporation
Tokyo 103-8210 (JP)

(72) Inventors:
• Hatada, Yuji
Mihara-shi, Hiroshima 723-0052 (JP)
• Ogawa, Akinori
Haga-gun, Tochigi 321-3497 (JP)

- Kageyama, Yasushi
Haga-gun, Tochigi 321-3497 (JP)
- Sato, Tsuyoshi
Haga-gun, Tochigi 321-3497 (JP)
- Araki, Hiroyuki
Haga-gun, Tochigi 321-3497 (JP)
- Sumitomo, Nobuyuki
Haga-gun, Tochigi 321-3497 (JP)
- Okuda, Mitsuyoshi
Haga-gun, Tochigi 321-3497 (JP)
- Saeki, Katsuhisa
Haga-gun, Tochigi 321-3497 (JP)

(74) Representative: VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)

(54) Alkaline proteases

(57) Provided are an alkaline protease wherein an amino acid residue at (a) position 84, (b) position 104, (c) position 256 or (d) position 369 of SEQ ID NO:1 or at a position corresponding thereto has been deleted or selected from: at position (a): an arginine residue, at position (b): a proline residue, at position (c): an alanine, serine, glutamine, valine, leucine, asparagine, glutamic acid or aspartic acid residue, and at position (d): an aspartic acid residue; an alkaline protease wherein an amino acid residue at (e) position 66 or 264, (f) position 57, each of 101 to 106, 136, 193 or 342, (g) position 46 or 205, (h) position 54, 119, 138, 148 or 195, (i) position 247, (j) position 124, (k) position 107 or (l) position 257 has been deleted or selected from: at position (e): a glutamine, aspartic acid or like residue, at position (f): a lysine, serine or like residue, at position (g): a tyrosine

or tryptophan residue, at position (h): a tryptophan, phenylalanine or like residue, at position (i): a tryptophan, phenylalanine or like residue, at position (j): an alanine or lysine residue, at position (k): a lysine, arginine or like residue, and at position (l): a valine or isoleucine residue; a gene encoding the alkaline protease; a recombinant vector containing the gene, a transformant containing the recombinant vector; and a detergent composition containing the alkaline protease.

The present invention makes it possible to provide alkaline proteases having activity even in the presence of a high concentration of fatty acids, having high specific activity and detergency and being useful as an enzyme to be incorporated in a detergent.

EP 1 209 233 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 12 7851

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 56927 A (NOVO NORDISK BIOTECH INC) 17 December 1998 (1998-12-17) * the whole document *	3-10	C12N15/57 C12N9/54 C12N1/21 C11D3/386
Y	EP 1 029 920 A (KAO CORP) 23 August 2000 (2000-08-23) * the whole document *	1-10	
Y	EP 0 130 756 A (GENENTECH INC) 9 January 1985 (1985-01-09) * the whole document * especially page 18, third paragraph and claim 15	1-10	
Y	WO 99 49057 A (CORREA PAUL ELLIOTT ;RUBINGH DONN NELTON (US); PROCTER & GAMBLE (U) 30 September 1999 (1999-09-30) * the whole document *	1,2,5-10	
Y	WO 99 49056 A (CORREA PAUL ELLIOTT ;RUBINGH DONN NELTON (US); PROCTER & GAMBLE (U) 30 September 1999 (1999-09-30) * the whole document *	1,2,5-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	WO 96 28556 A (PROCTER & GAMBLE) 19 September 1996 (1996-09-19) * the whole document * especially tabel 6	1-10	C12N C11D
Y	WO 92 08778 A (NOVONORDISK AS) 29 May 1992 (1992-05-29) * the whole document *	1,2,5-10	
-/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 August 2003	Examiner Van der Schaaf, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (Pct/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 12 7851

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	ESTELL D A ET AL: "ENGINEERING AN ENZYME BY SITE-DIRECTED MUTAGENESIS TO BE RESISTANT TO CHEMICAL OXIDATION" JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 260, no. 11, 10 June 1985 (1985-06-10), pages 6518-6521, XP000576091 * the whole document *	1,2,5-10	
D,A	EP 0 204 342 A (LION CORP) 10 December 1986 (1986-12-10)		
D,A	WO 88 01293 A (NOVO INDUSTRI AS) 25 February 1988 (1988-02-25)		
P,A	SAEKI KATSUHISA ET AL: "Novel oxidatively stable subtilisin-like serine proteases from alkaliphilic Bacillus spp.: Enzymatic properties, sequences, and evolutionary relationships." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 279, no. 2, 20 December 2000 (2000-12-20), pages 313-319, XP002238277 ISSN: 0006-291X		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	EP 0 251 446 A (GENENTECH INC) 7 January 1988 (1988-01-07) * the whole document *	3-10	
Y	WO 95 30010 A (PROCTER & GAMBLE) 9 November 1995 (1995-11-09) * the whole document *	3-10	
-/-			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 August 2003	Examiner Van der Schaal, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1603 03 B2 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 12 7851

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	WO 94 02618 A (GIST BROCADES NV ; MULLENERS LEONARDUS JOHANNES S (NL); MISSET ONNO) 3 February 1994 (1994-02-03) * the whole document *	1-10	
Y	WO 91 00345 A (NOVONORDISK AS) 10 January 1991 (1991-01-10) * the whole document *	3-10	
Y	WO 92 21760 A (COGNIS INC) 10 December 1992 (1992-12-10) * the whole document *	3-10	
Y	WO 99 20723 A (BAECK ANDRE CESAR ; BUSCH ALFRED (BE); OHTANI RYOHEI (JP); SHOWELL) 29 April 1999 (1999-04-29) * the whole document *	1-10	
Y	SIEZEN R J ET AL: "HOMOLOGY MODELLING AND PROTEIN ENGINEERING STRATEGY OF SUBTILASES, THE FAMILY OF SUBTILISIN-LIKE SERINE PROTEINASES" PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 4, no. 7, 1991, pages 719-737, XP002008733 ISSN: 0269-2139 * the whole document *	1-10	
Y	SIEZEN R J ET AL: "SUBTILASES: THE SUPERFAMILY OF SUBTILISIN-LIKE SERINE PROTEASES" PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 6, no. 3, March 1997 (1997-03), pages 501-523, XP000990399 ISSN: 0961-8368 * the whole document *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 August 2003	Examiner Van der Schaal, C
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/02 (P04001)



European Patent
Office

Application Number

EP 01 12 7851

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

European Patent
OfficeLACK OF UNITY OF INVENTION
SHEET BApplication Number
EP 01 12 7851

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1 2 6-10 partially

Alkaline protease wherein an amino acid residue at position 84, 104, 256 or 369 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue as described in claim 1

2. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position 66 or 264 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue mentioned under e) in claim 3

3. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position 57, 101, 102, 103, 105, 106, 136, 193 or 342 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue mentioned under f) in claim 3

4. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position 46 or 205 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue mentioned under g) in claim 3

5. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position 54 119 138 148 or 195 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue mentioned under h) in claim 3

6. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position 247 of SEQ ID NO 1 or at a position corresponding thereto has been deleted or selected from a residue mentioned under i) in claim 3

7. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number
EP 01 12 7851

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

124 of SEQ ID NO 1 or at a position corresponding thereto
has been deleted or selected from a residue mentioned under
j) in claim 3

8. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position
107 of SEQ ID NO 1 or at a position corresponding thereto
has been deleted or selected from a residue mentioned under
k) in claim 3

9. Claims: 3 -10 partially

Alkaline protease wherein an amino acid residue at position
257 of SEQ ID NO 1 or at a position corresponding thereto
has been deleted or selected from a residue mentioned under
l) in claim 3

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9856927	A	17-12-1998	US 5891701 A	06-04-1999
			AU 7957898 A	30-12-1998
			CN 1260003 T	12-07-2000
			EP 0988386 A2	29-03-2000
			JP 2001514529 T	11-09-2001
			WO 9856927 A2	17-12-1998
EP 1029920	A	23-08-2000	AU 732369 B2	26-04-2001
			AU 9457998 A	27-04-1999
			EP 1029920 A1	23-08-2000
			US 6376227 B1	23-04-2002
			CN 1280621 T	17-01-2001
			WO 9918218 A1	15-04-1999
EP 0130756	A	09-01-1985	US 2002064854 A1	30-05-2002
			US 4760025 A	26-07-1988
			AT 60797 T	15-02-1991
			AT 60356 T	15-02-1991
			AT 88750 T	15-05-1993
			AU 587960 B2	07-09-1989
			AU 2956884 A	03-01-1985
			AU 631797 B2	10-12-1992
			AU 3714989 A	23-11-1989
			AU 636109 B2	22-04-1993
			AU 3720889 A	07-12-1989
			DE 3484019 D1	28-02-1991
			DE 3484079 D1	14-03-1991
			DE 3486139 D1	03-06-1993
			DE 3486139 T2	11-11-1993
			DK 82293 A	08-07-1993
			DK 82393 A	08-07-1993
			DK 305984 A	18-02-1985
			EP 0130756 A1	09-01-1985
			EP 0247647 A1	02-12-1987
			EP 0246678 A1	25-11-1987
			EP 0357157 A2	07-03-1990
			ES 8604646 A1	01-07-1986
			ES 8701839 A1	01-03-1987
			ES 8608578 A1	01-12-1986
			HK 75393 A	06-08-1993
			HK 75493 A	06-08-1993
			HK 99293 A	30-09-1993
			IE 81141 B1	05-04-2000
			JP 2594533 B2	26-03-1997
			JP 60070075 A	20-04-1985
			JP 2889095 B2	10-05-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0130756	A		JP 6319534 A	22-11-1994
			JP 6315378 A	15-11-1994
			NZ 208612 A	25-09-1991
			NZ 224536 A	25-09-1991
			NZ 236052 A	25-03-1994
			NZ 244586 A	28-08-1995
			SG 67593 G	06-08-1993
			US 5310675 A	10-05-1994
			ZA 8404716 A	27-02-1985
			US 5371008 A	06-12-1994
			US 5371190 A	06-12-1994
			US 5972682 A	26-10-1999
			US 5472855 A	05-12-1995
			US 5955340 A	21-09-1999
			US 5763257 A	09-06-1998
			US 5801038 A	01-09-1998
			US 5700676 A	23-12-1997
			US 5652136 A	29-07-1997
			US 5185258 A	09-02-1993
WO 9949057	A	30-09-1999	AU 750336 B2	18-07-2002
			AU 2742699 A	18-10-1999
			BR 9909147 A	05-12-2000
			CA 2324422 A1	30-09-1999
			CN 1303437 T	11-07-2001
			EP 1082443 A1	14-03-2001
			WO 9949057 A1	30-09-1999
			JP 2002518993 T	02-07-2002
WO 9949056	A	30-09-1999	AU 2742499 A	18-10-1999
			BR 9909130 A	19-12-2000
			CA 2325568 A1	30-09-1999
			CN 1301305 T	27-06-2001
			EP 1082442 A1	14-03-2001
			WO 9949056 A1	30-09-1999
			JP 2002507426 T	12-03-2002
			US 6569663 B1	27-05-2003
WO 9628556	A	19-09-1996	AU 5092796 A	02-10-1996
			BR 9607677 A	07-07-1998
			CA 2214395 A1	19-09-1996
			CN 1183809 A	03-06-1998
			CZ 9702799 A3	14-01-1998
			EP 0813601 A2	29-12-1997
			HU 9801638 A2	28-10-1998
			JP 11501814 T	16-02-1999

EPO FORM P0559

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9628556	A		WO 9628556 A2	19-09-1996
			US 6451574 B1	17-09-2002
			ZA 9601820 A	10-09-1996
WO 9208778	A	29-05-1992	AT 135395 T	15-03-1996
			AU 2943092 A	15-06-1993
			BR 9107020 A	03-05-1994
			CA 2095853 A1	15-05-1992
			DE 69117970 D1	18-04-1996
			DE 69117970 T2	02-10-1996
			WO 9208778 A1	29-05-1992
			EP 0557377 A1	01-09-1993
			FI 932186 A	13-05-1993
			JP 6501509 T	17-02-1994
			MX 9102016 A1	08-07-1992
			RU 2108373 C1	10-04-1998
			US 5389307 A	14-02-1995
EP 0204342	A	10-12-1986	JP 1713681 C	27-11-1992
			JP 3079987 B	20-12-1991
			JP 61280268 A	10-12-1986
			JP 1644201 C	28-02-1992
			JP 3000997 B	09-01-1991
			JP 61280278 A	10-12-1986
			JP 1631586 C	26-12-1991
			JP 2055034 B	26-11-1990
			JP 62146594 A	30-06-1987
			CA 1297821 C	24-03-1992
			DE 3683802 D1	19-03-1992
			DK 268686 A	07-12-1986
			EP 0204342 A2	10-12-1986
			US 4797362 A	10-01-1989
WO 8801293	A	25-02-1988	AT 92957 T	15-08-1993
			DE 3787009 D1	16-09-1993
			DE 3787009 T2	17-03-1994
			DK 197388 A ,B,	12-04-1988
			WO 8801293 A1	25-02-1988
			EP 0277216 A1	10-08-1988
			JP 2559439 B2	04-12-1996
			JP 1500642 T	09-03-1989
EP 0251446	A	07-01-1988	AT 116365 T	15-01-1995
			AU 614929 B2	19-09-1991
			AU 7228187 A	05-11-1987
			CA 1341280 C	07-08-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0251446	A		DE 3750916 D1	09-02-1995
			DE 3750916 T2	01-06-1995
			DK 221787 A	31-10-1987
			EP 0251446 A2	07-01-1988
			ES 2068181 T3	16-04-1995
			GR 3015388 T3	30-06-1995
			IE 65767 B1	15-11-1995
			JP 2772295 B2	02-07-1998
			JP 10042876 A	17-02-1998
			JP 1085075 A	30-03-1989
			JP 2647845 B2	27-08-1997
			NZ 240670 A	26-05-1995
			SG 9590699 A2	01-09-1995
			US 5371008 A	06-12-1994
			US 5371190 A	06-12-1994
			US 5972682 A	26-10-1999
			US 5472855 A	05-12-1995
			US 5955340 A	21-09-1999
			US 5763257 A	09-06-1998
			US 5801038 A	01-09-1998
			US 5700676 A	23-12-1997
			US 5652136 A	29-07-1997
			US 5185258 A	09-02-1993
			US 5182204 A	26-01-1993
			US 5204015 A	20-04-1993
			US 6465235 B1	15-10-2002
			US 5352594 A	04-10-1994
WO 9530010	A	09-11-1995	US 6436690 B1	20-08-2002
			AU 2159195 A	29-11-1995
			AU 2293195 A	29-11-1995
			BR 9507593 A	23-09-1997
			BR 9507597 A	07-10-1997
			CA 2189426 A1	09-11-1995
			CA 2189428 A1	09-11-1995
			CN 1151757 A	11-06-1997
			CN 1151761 A	11-06-1997
			CZ 9603216 A3	14-05-1997
			EP 0758388 A1	19-02-1997
			EP 0758373 A1	19-02-1997
			FI 964411 A	01-11-1996
			HU 75559 A2	28-05-1997
			JP 9511652 T	25-11-1997
			JP 9512433 T	16-12-1997
			NO 964590 A	30-10-1996
			WO 9530010 A1	09-11-1995

EPO FORM P4489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9530010	A		WO 9529979 A1	09-11-1995
			US 6440717 B1	27-08-2002
			ZA 9502220 A	14-12-1995
			AU 7870394 A	03-04-1995
			BR 9407502 A	07-01-1997
			CA 2170491 A1	23-03-1995
			CN 1134728 A , B	30-10-1996
			CZ 9600791 A3	12-06-1996
			EP 0719339 A1	03-07-1996
			HU 74222 A2	28-11-1996
			JP 9502610 T	18-03-1997
			NO 961067 A	15-05-1996
			TR 960111 A2	21-06-1996
			WO 9507991 A2	23-03-1995
WO 9402618	A	03-02-1994	AU 682314 B2	02-10-1997
			AU 4700693 A	14-02-1994
			CA 2139928 A1	03-02-1994
			WO 9402618 A1	03-02-1994
			EP 0717778 A1	26-06-1996
			FI 950168 A	10-03-1995
			JP 7508887 T	05-10-1995
			PL 307132 A1	02-05-1995
WO 9100345	A	10-01-1991	US 6287841 B1	11-09-2001
			AT 196774 T	15-10-2000
			AU 5956690 A	17-01-1991
			BR 9007477 A	02-06-1992
			CA 2062732 A1	27-12-1990
			DE 69033644 D1	09-11-2000
			DE 69033644 T2	10-05-2001
			DE 945502 T1	17-10-2002
			WO 9100345 A1	10-01-1991
			DK 479870 T3	17-04-2001
			EP 0479870 A1	15-04-1992
			EP 0945502 A1	29-09-1999
			ES 2152209 T3	01-02-2001
			FI 102907 B1	15-03-1999
			FI 990023 A	08-01-1999
			JP 4505856 T	15-10-1992
			JP 3343115 B2	11-11-2002
			JP 2002315591 A	29-10-2002
			JP 2002272488 A	24-09-2002
			KR 258459 B1	01-06-2000
			US 5665587 A	09-09-1997
			US 6197567 B1	06-03-2001

EPO FORM P0469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9221760 A	10-12-1992	US 5340735 A	23-08-1994
		AT 203771 T	15-08-2001
		DE 69231974 D1	06-09-2001
		DE 69231974 T2	04-04-2002
		DK 590012 T3	12-11-2001
		EP 0590012 A1	06-04-1994
		ES 2164644 T3	01-03-2002
		GR 3037002 T3	31-01-2002
		JP 6508264 T	22-09-1994
		WO 9221760 A1	10-12-1992
		US 5500364 A	19-03-1996
		US 6403331 B1	11-06-2002
		US 5985639 A	16-11-1999
		US 6136553 A	24-10-2000
WO 9920723 A	29-04-1999	AU 758371 B2	20-03-2003
		AU 1118199 A	10-05-1999
		AU 742573 B2	10-01-2002
		AU 1196999 A	10-05-1999
		AU 742632 B2	10-01-2002
		AU 1197199 A	10-05-1999
		AU 742694 B2	10-01-2002
		AU 1199499 A	10-05-1999
		AU 1199699 A	10-05-1999
		AU 1276299 A	10-05-1999
		AU 8733701 A	03-01-2002
		BR 9813115 A	15-08-2000
		BR 9813260 A	22-08-2000
		BR 9813266 A	20-11-2001
		BR 9813879 A	26-09-2000
		BR 9814097 A	03-10-2000
		BR 9815230 A	02-10-2001
		CA 2306794 A1	29-04-1999
		CA 2306894 A1	29-04-1999
		CA 2307638 A1	29-04-1999
		CA 2307640 A1	29-04-1999
		CA 2308113 A1	29-04-1999
		CA 2308206 A1	29-04-1999
		CN 1279720 T	10-01-2001
		CN 1279721 T	10-01-2001
		CN 1306577 T	01-08-2001
		CN 1286723 T	07-03-2001
		CN 1286724 T	07-03-2001
		CN 1327476 T	19-12-2001
		CZ 20001477 A3	12-12-2001
		CZ 20001478 A3	12-12-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 7851

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-08-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9920723 A		CZ 20001479 A3	16-01-2002
		CZ 20001493 A3	14-11-2001
		EG 21711 A	27-02-2002
		EG 22075 A	31-07-2002
		EP 0913458 A1	06-05-1999
		EP 1025239 A2	09-08-2000
		EP 1025194 A1	09-08-2000
		EP 1082404 A2	14-03-2001
		EP 1027418 A1	16-08-2000
		EP 1025240 A2	09-08-2000
		EP 1025241 A2	09-08-2000
		HU 0100859 A2	28-06-2001
		HU 0103080 A2	28-12-2001
		HU 0104539 A2	29-04-2002
		JP 2001520305 T	30-10-2001
		JP 2001520307 T	30-10-2001
		JP 2001520308 T	30-10-2001
		JP 2001520044 T	30-10-2001
		JP 2001520045 T	30-10-2001

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82